The Biotechnology Industry Organization (BIO) Investor Forum is a national investor conference held in the US. Participants of the forum include leading private and emerging public biotech companies, venture and private equity investors in healthcare, and investors interested in buying or selling. Business development executives from leading pharmaceutical and biotech companies participating in the forum will have the opportunity for networking and exploring for the kinds of deals they are looking for.
At this year’s conference, Chairman/CEO of Advaxis Inc., a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, will discuss recent developments in the areas of clinical trials and financing.
Other topics slated to be discussed include:
– First patient group dosing in US-based, Phase II cervical dysplasia (CIN) trial
– Drug Controller General of India (DCGI) clearance to proceed with a India-based, Phase II cervical cancer trial
– National Cancer Institute — Gynecologic Oncology Group’s trial in cervix cancer
– CRUK trial in Head and Neck cancer
– Collaborative research and development agreement (CRADA) signing with the Department of Homeland Security (DHS) to study Listeria in animals
– $7.5 million in financing agreement with life science fund
Read the news release at Market Watch.
